PDGFRα and β are differently expressed in glioma, and in silico survival analysis revealed opposite effects [33] and prognostic alternatives, unmasking the complexity of a therapeutic strategy targeting PDGFRs. The gene discussed is PDGFRA; the disease is central nervous system cancer.